Anaesthetic maker points to low pain way into Biotechs
Article Abstract:
Chiroscience has a number of promising drugs in its portfolio, and has a strong cash position due to a number of deals. The company has a marketing agreement with Zeneca, which has invested 15 million pounds sterling in Chiroscience and is planning marketing for Chirocaine, a local anaesthetic. There is also a collaboration agreement with Schering Plough in relation to an asthma drug, and Bristol Mayers Squibb backs a cancer treatment. The company offers relative security for investors seeking a biotech investment.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Cambridge Antibody
Article Abstract:
Cambridge Antibody is a drug discovery company that has seen a drop in its stock price following a stock flotation in 1997. The company was spun off from the United Kingdom Medical Research Council and plays a major role in discovering monoclonal antibodies used in combating human diseases. The technology is leased to clients such as Genetech and Pfizer. The company is likely to need additional capital prior to marketing any drugs, but uncertainty has been reduced through technology licenses.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Cortecs International
Article Abstract:
Cortecs International is a UK drug developer which say a drop in operating losses in the 12 months to Jun 1995. The company has beenfited from a rise in sales of a blood test kit, Helisal Rapid, which is used by Astra. Cortecs International has also signed distribution agreementswith Boehringer and Zenyaku for Helisal. The company has other diagnostic kits and treatments which show promise, and the company's profit is forecast at 0.5 million pounds sterling for 1996 by Henry Cooke Lumsden.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Partnerships in African crop biotech. Partnering up in Q3. International regional collaborations are paying off
- Abstracts: Acquisitions to follow radical shift. Yule Catto. BTP
- Abstracts: Downturn rubs magic off the tiger legend. A lousy company by any other name. Unravelling an enigma
- Abstracts: Rate doubts hit the yen. Japan: interest rate rise. Japan: glimmers of optimism
- Abstracts: Lloyds jumps to the top. Forex dealers target UK investors from abroad